PharmEasy to pick up 66.1% stake in Thyrocare for Rs 4,546 crore

Online medicine delivery firm PharmEasy on Friday announced that its parent API Holdings Ltd (API) will acquire 66.1 per cent stake in Thyrocare for Rs 4,546 crore from Dr A Velumani and affiliates.

Thyrocare is the largest B2B player in the diagnostics space and has a network of 3,330 collection centres across in 2,000 towns in India.

On the addition of Thyrocare into its portfolio, Mr Siddharth Shah, CEO, API Holdings said: “We are delighted to be partnering Thyrocare. We will provide world class customer experience in diagnostics, rivalling our pharmacy experience by leveraging technology, and building on top of the massive scale & truly pan-India presenceof Thyrocare. It is our aim to deliver all outpatient healthcare products & services to every Indian within 24 hours.

Dr A Velumani will be separately acquiring a minority non-controlling stake, of less than 5 per cent in API as part of a series of equity investments by existing and new investors of API.

“I am excited about this relationship, unique of its kind in Indian Healthcare Industry. The unique reach and strength of Thyrocare in Diagnostics blended with young and dynamic team of PharmEasy will bring in better healthcare solutions for common man nationwide,” said Dr A Velumani, Chairman & MD of Thyrocare.

The combined entity will have the ability to provide diagnostics and pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement.

The landmark partnership will bring seamless, tech-enabled healthcare for consumers, doctors and suppliers, it further said.

The transaction is subject to regulatory and other applicable customary approvals.

Docon Technologies Pvt Ltd, a 100 per cent subsidiary of API, will be the acquirer and shall make an open offer for an additional 26 per cent stake.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor